Correction to: *Nature Communications* 10.1038/s41467-019-11845-y, published online 29 August 2019.

In the original version of this manuscript, in the discussion section in the seventh paragraph, the gene symbol for *PARP14* was incorrectly given as *PAR14* and incorrect citations of the literature were given. The incorrect version read 'We would like to highlight variants in *HLA-F*, *PAR14* and *GAB2* controlled methylation sites in *USP35*. *HLA-F* is part of the nonclassical *HLA-Ib* genes, which are mono- or oligomorphic^46^. Surface expression of *HLA-F* has been demonstrated on activated T, B and NK cells, and serum IgG autoantibodies against *HLA-F* have been detected in SLE patients and correlated with disease activity^63--65^. *PARP14* encodes for poly(ADP-ribose) polymerase (PARP) protein family 14 and is involved in cellular maintenance and cell fate decisions, such as cell-cycle progression, metabolic pathways and ribosome biogenesis^66^. Its role in SLE and autoimmune disease has not been defined but it has been shown to regulate glycolysis via IL-4 in B lymphocytes^67^ and to promote survival of cancer cells^67--69^.'

The correct version replaces these sentences with 'We would like to highlight variants in *HLA-F*, *PARP14* and *GAB2* controlled methylation sites in *USP35*. *HLA-F* is part of the nonclassical *HLA-Ib* genes, which are mono- or oligomorphic^46^. Surface expression of *HLA-F* has been demonstrated on activated T, B and NK cells, and serum IgG autoantibodies against *HLA-F* have been detected in SLE patients and correlated with disease activity^63--65^. *PARP14* encodes for poly(ADP-ribose) polymerase (PARP) protein family 14 and assists in post-translational ribosylation modification of target proteins. Its role in SLE and autoimmune disease has not been defined but it has been shown to regulate glycolysis via IL-4 in B lymphocytes^66^, promote survival of cancer cells^67^, and regulate macrophage activation^68^.'

Further, the original refs. ^66--69^ were replaced with the following corrected refs. ^66--68^ and all following references were renumbered.

All of these errors have now been corrected in the HTML and PDF versions of the article.
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